Overview

A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Status:
Completed
Trial end date:
2007-10-09
Target enrollment:
Participant gender:
Summary
This is a Phase III trial designed to demonstrate that casopitant when added to dexamethasone and ondansetron is more effective in the prevention of vomiting then dexamethasone and ondansetron alone, in patients who receive a cisplatin-based highly emetogenic chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant
Cisplatin
Dexamethasone
Ondansetron